China Anti Aging Therapeutics Market Analysis

China Anti-Aging Therapeutics Market Executive Summary

China's anti-aging therapeutics market size is at around $49 Mn in 2022 and is projected to reach $183 Mn in 2030, exhibiting a CAGR of 18.03% during the forecast period. According to the South China Morning Post's most recent healthcare report, China's combined pharmaceutical and biopharma R&D expenditure will increase at a compound annual rate of 23% until 2023, reaching $49 Bn. By then, 23% of the global total for drug finding and testing will be spent on pharmaceutical and biopharma R&D in China. By 2021, sales of biopharmaceuticals in China are expected to nearly double from their 2016 level to $50 Bn. Before 2030, the SCMP research found that China could be on par with America and Europe in terms of its ability to produce best-in-class medications. China's healthcare market was the second-largest in the world in 2018, spending $3.5 trillion in that sector.

Aging is the negative change in an organism's overall function that happens as it gets older. The theory of genetic mutation, telomere loss, somatic mutation, free radical damage, immune disorder, mitochondrial dysfunction, and autophagy dysfunction are some of the biological processes that contribute to the highly complex biological process of aging. Despite China's longstanding reputation as a nation that values and honors its elders, the country is currently experiencing a surge in anti-aging initiatives. All groups exhibit enthusiasm for anti-aging products, according to observers. For the first time, a novel cause of cellular senescence has been discovered using a genome-wide CRISPR-based screening technique. According to Chinese experts, it can be incorporated into novel ways to postpone aging and ward off diseases linked to it. The study team showed that knocking out, or disabling, some genes by CRISPR can prevent the aging of human mesenchymal precursor cells by screening and finding more than 100 genes responsible for the aging of human cells. (hMPCs). KAT7 (a histone acetyltransferase) is one of the senility-causing genes and a key factor in aging. The innovative gene therapy, which depends on turning off a specific gene or using KAT7 inhibitors, could potentially extend the lives of mammals. Furthermore, it might delay the deterioration of human liver cells. It implies a significant possibility for its use in translational medicine to combat human aging.

Market Dynamics

Market Growth Drivers Analysis

One factor influencing the market is the rising concern in China about how one appears on social media. China's aging population, which is one of the fastest-growing in the world, is one of the factors further igniting this anti-aging trend, according to WHO. Because of the differences in culture and society, these groups are more ready than their western counterparts to invest time, money, and effort into maintaining a youthful appearance. The China anti-aging therapeutics market's expansion is also due to social media and e-commerce. To capitalize on this generation's potential for online shopping, Alibaba launched its "Taobao for Elders" initiative at the beginning of 2018. The online lifestyle community Xiaohongshu, also known as "Little Red Book," is well-recognized and caters to young people in China. With the recent debut of Laohongshu (literally, "Old Red Book"), it began to include the elderly.

In the anti-aging market, personalized care-focused AI is commonly seen in technical R&D and client-focused marketing. Fermentation and synthetic biotechnology, in particular, are currently the China anti-aging therapeutics market's star components and are of natural or biotechnological origin.

Market Restraints

Companies seeking to market new anti-aging therapies in China may find the regulatory environment to be complicated and difficult. Delays and higher expenses for businesses may result from this, which may deter market innovation and investment. China has a long tradition of using traditional Chinese medicine, and it is still widely practiced today. Modern anti-aging treatments may not always be preferred by patients, which could impede the China anti-aging therapeutics market's expansion.

Competitive Landscape

Key Players

• BeiGene (CHN)
• Chi-Med (CHN)
• CStone Pharmaceuticals (CHN)
• Harbour BioMed (CHN)
• Hua Medicine (CHN)
• Rejuvenate Bio
• Rejenevie Therapeutics
• MyMD Pharmaceuticals
• Intervene Immune
• CohBar

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA), formerly known as the China Food and Drug Administration, is the regulatory body in charge of overseeing the licensing and control of anti-aging medications in China. (CFDA). In China, the NMPA is in charge of regulating all pharmaceutical goods, including anti-aging medications. Before pharmaceutical goods are permitted for sale in China, the agency is in charge of assessing their quality, safety, and efficacy. Clinical trial requirements, product registration requirements, and post-market surveillance requirements are all part of the complete regulatory framework for pharmaceutical products that the NMPA has put in place. Before their products can be sold in the Chinese market, businesses looking to develop and market anti-aging drugs in China must abide by these rules and receive approval from the NMPA. For patients in China, the NMPA has lately improved access to modern treatments by streamlining the drug approval procedure. These adjustments include accelerated review processes for specific drug classes as well as modifications to the clinical trial specifications for specific drugs.